Assistant professor Erasmus School of Health Policy & Management
- Location
- Burg. Oudlaan 50, Rotterdam
- Room
- J8-23
- blommestein@eshpm.eur.nl
More information
‹ Back to overview
Profile
- DE Issa, Avinash Dinmohamed, MJ Wondergem, Hedwig Blommestein, PC Huijgens, Elly Lugtenburg, O Visser, S Zweegman & MED Chamuleau (2020) - A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL inThe Netherlands - Leukemia & Lymphoma, 62 (3), 549-559 - doi: 10.1080/10428194.2020.1842394 - [link]
- Marianne Luyendijk, RWM Vernooij, Hedwig Blommestein, S Siesling & Carin Groot (2020) - Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review - Value in Health, 23 (11), 1497-1508 - doi: 10.1016/j.jval.2020.05.008 - [link]
- Frederick Thielen, Maite Houwing, Marjon Cnossen, IA Hadithy-Irgiztseva, Jan Hazelzet, Carin Groot, Anne Pagter & Hedwig Blommestein (2020) - Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country - Pediatric Blood & Cancer, 67 (9) - doi: 10.1002/pbc.28588
- Hedwig Blommestein, CHY van Beurden-Tan, Margreet Franken, Carin Groot, Pieter Sonneveld & S Zweegman (2019) - Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis - Haematologica, 104 (5), 1026-1035 - doi: 10.3324/haematol.2018.206912
- Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - European Journal of Surgical Oncology, 45 (5), 825-831 - doi: 10.1016/j.ejso.2019.01.225 - [link]
- Frederick Thielen, Hedwig Blommestein, LEM Oosten, FG Calkoen, AC Lankester, JJ Zwaginga, K Le Blanc, A Redondo, F Sánchez?Guijo, M Algeri, F (Franco) Locatelli, WE Fibbe & Carin Groot (2018) - Second?line treatment for acute graft?versus?host disease with mesenchymal stromal cells: A decision model. - European Journal of Haematology, 101 (5), 676-683 - doi: 10.1111/ejh.13158 - [link]
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- CHY van Beurden-Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Reply to X. Armoiry et al - Journal of Clinical Oncology, 35 (25), 2976 - doi: 10.1200/JCO.2017.73.7569
- J Mihajlovi?, P Bax, E van Breugel, Hedwig Blommestein, M Hoogendoorn, W Hospes & MJ Postma (2017) - Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion - Clinical Therapeutics, 39 (6), 1221-1232 - doi: 10.1016/j.clinthera.2017.05.342
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- Hedwig Blommestein, Carin Groot & S Zweegman (2017) - De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg - Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281
- CHY van Beurden-Tan, MG Franken, Hedwig Blommestein, CA Uyl-de Groot & Pieter Sonneveld (2017) - Untitled Reply - Journal of Clinical Oncology, 35 (25), 2976-+ - doi: 10.1200/jco.2017.73.7569
- Chrissy Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma - Journal of Clinical Oncology, 35 (12), 1312-+ - doi: 10.1200/jco.2016.71.1663
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- Frederick Thielen, Hedwig Blommestein & Carin Groot (2016) - Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease - Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110 - doi: 10.1016/j.bbmt.2016.08.022
- Hedwig Blommestein, PC Huijgens & Carin Groot (2016) - De toegevoegde waarde van gegevens uit de dagelijkse praktijk. - Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Hedwig Blommestein, Margreet Franken & Carin Groot (2015) - A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry - Pharmacoeconomics (Print) - doi: 10.1007/s40273-015-0260-4
- Hedwig Blommestein, DE Issa, M Pompen, G Ten Hoor, M Hogendoorn, P Joosten, S Zweegman, PC Huijgens & Carin Groot (2014) - Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study - European Journal of Haematology, 92, 398-406 - doi: 10.1111/ejh.12264
- Hedwig Blommestein, Margreet Franken, Silvia Verelst, M (Michel) van Agthoven, PC Huijgens & Carin Groot (2014) - Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? - Netherlands Journal of Medicine, 72 (4), 235-241 - [link]
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
- Hedwig Blommestein, Silvia Verelst, PC Huijgens, NMA Blijlevens, Jan Cornelissen & Carin Groot (2012) - Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study - Annals of Hematology, 91 (12), 1945-1952 - doi: 10.1007/s00277-012-1530-2
- Annemieke Leunis, Hedwig Blommestein, PC Huijgens, NMA Blijlevens, Mojca Lavrencic & Carin Groot (2012) - The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands - Leukemia Research, 37, 245-250 - doi: 10.1016/j.leukres.2012.09.018
- Hedwig Blommestein (2016) - The added value of real-world evidence - EUR
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA
- DE Issa, Avinash Dinmohamed, MJ Wondergem, Hedwig Blommestein, PC Huijgens, Elly Lugtenburg, O Visser, S Zweegman & MED Chamuleau (2020) - A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL inThe Netherlands - Leukemia & Lymphoma, 62 (3), 549-559 - doi: 10.1080/10428194.2020.1842394 - [link]
- Marianne Luyendijk, RWM Vernooij, Hedwig Blommestein, S Siesling & Carin Groot (2020) - Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review - Value in Health, 23 (11), 1497-1508 - doi: 10.1016/j.jval.2020.05.008 - [link]
- Frederick Thielen, Maite Houwing, Marjon Cnossen, IA Hadithy-Irgiztseva, Jan Hazelzet, Carin Groot, Anne Pagter & Hedwig Blommestein (2020) - Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country - Pediatric Blood & Cancer, 67 (9) - doi: 10.1002/pbc.28588
- Hedwig Blommestein, CHY van Beurden-Tan, Margreet Franken, Carin Groot, Pieter Sonneveld & S Zweegman (2019) - Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis - Haematologica, 104 (5), 1026-1035 - doi: 10.3324/haematol.2018.206912
- Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - European Journal of Surgical Oncology, 45 (5), 825-831 - doi: 10.1016/j.ejso.2019.01.225 - [link]
- Frederick Thielen, Hedwig Blommestein, LEM Oosten, FG Calkoen, AC Lankester, JJ Zwaginga, K Le Blanc, A Redondo, F Sánchez?Guijo, M Algeri, F (Franco) Locatelli, WE Fibbe & Carin Groot (2018) - Second?line treatment for acute graft?versus?host disease with mesenchymal stromal cells: A decision model. - European Journal of Haematology, 101 (5), 676-683 - doi: 10.1111/ejh.13158 - [link]
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- CHY van Beurden-Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Reply to X. Armoiry et al - Journal of Clinical Oncology, 35 (25), 2976 - doi: 10.1200/JCO.2017.73.7569
- J Mihajlovi?, P Bax, E van Breugel, Hedwig Blommestein, M Hoogendoorn, W Hospes & MJ Postma (2017) - Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion - Clinical Therapeutics, 39 (6), 1221-1232 - doi: 10.1016/j.clinthera.2017.05.342
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- Hedwig Blommestein, Carin Groot & S Zweegman (2017) - De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg - Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281
- CHY van Beurden-Tan, MG Franken, Hedwig Blommestein, CA Uyl-de Groot & Pieter Sonneveld (2017) - Untitled Reply - Journal of Clinical Oncology, 35 (25), 2976-+ - doi: 10.1200/jco.2017.73.7569
- Chrissy Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma - Journal of Clinical Oncology, 35 (12), 1312-+ - doi: 10.1200/jco.2016.71.1663
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- Frederick Thielen, Hedwig Blommestein & Carin Groot (2016) - Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease - Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110 - doi: 10.1016/j.bbmt.2016.08.022
- Hedwig Blommestein, PC Huijgens & Carin Groot (2016) - De toegevoegde waarde van gegevens uit de dagelijkse praktijk. - Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Hedwig Blommestein, Margreet Franken & Carin Groot (2015) - A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry - Pharmacoeconomics (Print) - doi: 10.1007/s40273-015-0260-4
- Hedwig Blommestein, DE Issa, M Pompen, G Ten Hoor, M Hogendoorn, P Joosten, S Zweegman, PC Huijgens & Carin Groot (2014) - Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study - European Journal of Haematology, 92, 398-406 - doi: 10.1111/ejh.12264
- Hedwig Blommestein, Margreet Franken, Silvia Verelst, M (Michel) van Agthoven, PC Huijgens & Carin Groot (2014) - Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? - Netherlands Journal of Medicine, 72 (4), 235-241 - [link]
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
- Hedwig Blommestein, Silvia Verelst, PC Huijgens, NMA Blijlevens, Jan Cornelissen & Carin Groot (2012) - Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study - Annals of Hematology, 91 (12), 1945-1952 - doi: 10.1007/s00277-012-1530-2
- Annemieke Leunis, Hedwig Blommestein, PC Huijgens, NMA Blijlevens, Mojca Lavrencic & Carin Groot (2012) - The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands - Leukemia Research, 37, 245-250 - doi: 10.1016/j.leukres.2012.09.018
- DE Issa, Avinash Dinmohamed, MJ Wondergem, Hedwig Blommestein, PC Huijgens, Elly Lugtenburg, O Visser, S Zweegman & MED Chamuleau (2020) - A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL inThe Netherlands - Leukemia & Lymphoma, 62 (3), 549-559 - doi: 10.1080/10428194.2020.1842394 - [link]
- Marianne Luyendijk, RWM Vernooij, Hedwig Blommestein, S Siesling & Carin Groot (2020) - Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review - Value in Health, 23 (11), 1497-1508 - doi: 10.1016/j.jval.2020.05.008 - [link]
- Frederick Thielen, Maite Houwing, Marjon Cnossen, IA Hadithy-Irgiztseva, Jan Hazelzet, Carin Groot, Anne Pagter & Hedwig Blommestein (2020) - Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country - Pediatric Blood & Cancer, 67 (9) - doi: 10.1002/pbc.28588
- Hedwig Blommestein, CHY van Beurden-Tan, Margreet Franken, Carin Groot, Pieter Sonneveld & S Zweegman (2019) - Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis - Haematologica, 104 (5), 1026-1035 - doi: 10.3324/haematol.2018.206912
- Brenda Leeneman, Margreet Franken, VMH Coupe, MP Hendriks, Wim Kruit, PW Plaisier, S van Ruth, J Verstijnen, M Wouters, Hedwig Blommestein & Carin Groot (2019) - Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma - European Journal of Surgical Oncology, 45 (5), 825-831 - doi: 10.1016/j.ejso.2019.01.225 - [link]
- Frederick Thielen, Hedwig Blommestein, LEM Oosten, FG Calkoen, AC Lankester, JJ Zwaginga, K Le Blanc, A Redondo, F Sánchez?Guijo, M Algeri, F (Franco) Locatelli, WE Fibbe & Carin Groot (2018) - Second?line treatment for acute graft?versus?host disease with mesenchymal stromal cells: A decision model. - European Journal of Haematology, 101 (5), 676-683 - doi: 10.1111/ejh.13158 - [link]
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- CHY van Beurden-Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Reply to X. Armoiry et al - Journal of Clinical Oncology, 35 (25), 2976 - doi: 10.1200/JCO.2017.73.7569
- J Mihajlovi?, P Bax, E van Breugel, Hedwig Blommestein, M Hoogendoorn, W Hospes & MJ Postma (2017) - Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion - Clinical Therapeutics, 39 (6), 1221-1232 - doi: 10.1016/j.clinthera.2017.05.342
- N Büyükkaramikli, Hedwig Blommestein, R Riemsma, N Armstrong, FJ Clay, J Ross, G Worthy, Hans Severens, J Kleijnen & Maiwenn Al (2017) - Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0528-y
- Hedwig Blommestein, Carin Groot & S Zweegman (2017) - De econoom en de hematoloog: kosten, effecten en verantwoorde toegang tot zorg - Nederlands Tijdschrift voor Hematologie, 14 (6), 273-281
- CHY van Beurden-Tan, MG Franken, Hedwig Blommestein, CA Uyl-de Groot & Pieter Sonneveld (2017) - Untitled Reply - Journal of Clinical Oncology, 35 (25), 2976-+ - doi: 10.1200/jco.2017.73.7569
- Chrissy Tan, Margreet Franken, Hedwig Blommestein, Carin Groot & Pieter Sonneveld (2017) - Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma - Journal of Clinical Oncology, 35 (12), 1312-+ - doi: 10.1200/jco.2016.71.1663
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- Frederick Thielen, Hedwig Blommestein & Carin Groot (2016) - Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease - Biology of Blood and Marrow Transplantation, 22 (11), 2109-2110 - doi: 10.1016/j.bbmt.2016.08.022
- Hedwig Blommestein, PC Huijgens & Carin Groot (2016) - De toegevoegde waarde van gegevens uit de dagelijkse praktijk. - Nederlands Tijdschrift voor Hematologie, 13 (5), 206-208
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens & Maiwenn Al (2016) - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene - Pharmacoeconomics (Online), 34 (1), 23-31 - doi: 10.1007/s40273-015-0318-3
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Hedwig Blommestein, Margreet Franken & Carin Groot (2015) - A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry - Pharmacoeconomics (Print) - doi: 10.1007/s40273-015-0260-4
- Hedwig Blommestein, DE Issa, M Pompen, G Ten Hoor, M Hogendoorn, P Joosten, S Zweegman, PC Huijgens & Carin Groot (2014) - Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study - European Journal of Haematology, 92, 398-406 - doi: 10.1111/ejh.12264
- Hedwig Blommestein, Margreet Franken, Silvia Verelst, M (Michel) van Agthoven, PC Huijgens & Carin Groot (2014) - Access to expensive cancer drugs in Dutch daily practice: Should we be concerned? - Netherlands Journal of Medicine, 72 (4), 235-241 - [link]
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2014) - Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? - Value in Health, 17, 245-253 - doi: 10.1016/j.jval.2013.12.009
- Hedwig Blommestein, Silvia Verelst, PC Huijgens, NMA Blijlevens, Jan Cornelissen & Carin Groot (2012) - Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study - Annals of Hematology, 91 (12), 1945-1952 - doi: 10.1007/s00277-012-1530-2
- Annemieke Leunis, Hedwig Blommestein, PC Huijgens, NMA Blijlevens, Mojca Lavrencic & Carin Groot (2012) - The costs of initial treatment for patients with acute myeloid leukemia in the Netherlands - Leukemia Research, 37, 245-250 - doi: 10.1016/j.leukres.2012.09.018
- Hedwig Blommestein (2016) - The added value of real-world evidence - EUR
- Hedwig Blommestein (2016) - The added value of real-world evidence - EUR
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma - Erasmus Universiteit Rotterdam - GE-iMTA
Zorginstituut Nederland
- Begindatum goedkeuring
- november 2020
- Einddatum goedkeuring
- oktober 2023
- Plaats
- DIEMEN
- Beschrijving
- Lid van de Wetenscappelijke Adviesraad (WAR)
Zorginstituut Nederland
- Begindatum goedkeuring
- november 2020
- Einddatum goedkeuring
- oktober 2023
- Plaats
- DIEMEN
- Beschrijving
- Lid van de Wetenscappelijke Adviesraad (WAR)
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4585M
Health Technology Assessment
- Year
- 2021
- Year Level
- master, master, master
- Course Code
- GW4546M
Master HEPL-HE 2021-2022
- Year
- 2021
- Course Code
- GWMTTHEPL
Health Technology Assessment (Eu-HEM)
- Level
- master
- Year
- 2021
- Year Level
- master
- Course Code
- GW4585M
Health Technology Assessment
- Year
- 2021
- Year Level
- master, master, master
- Course Code
- GW4546M
Master HEPL-HE 2021-2022
- Year
- 2021
- Course Code
- GWMTTHEPL